-
Mashup Score: 1Case Presentation: An 83-Year-Old Man with Biochemically Recurrent Metastatic Castration-Sensitive Prostate Cancer (mCSPC) - 1 year(s) ago
Sheela Tejwani, MD, presents the case of an 83-year-old man with mCSPC, and shares her first impressions as compared to her typical patients.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
At the 2022 Large Urology Group Practice Association (LUGPA) annual meeting, Alicia Morgans presented on couplet versus triplet therapy for metastatic castrate-sensitive prostate cancer (mCSPC). Biography: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Related Content: APCCC 2022:…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
#mCSPC Couplet vs Triplet Therapy. #LUGPA22 presentation by @CaPsurvivorship @DanaFarber. #WatchNow on UroToday > https://t.co/JZvzZ3SxOZ @UrologyUS https://t.co/yNhGAtm9JR
-
-
Mashup Score: 0How Triplets and Doublets Compare in Metastatic Castration-Sensitive Prostate Cancer - 1 year(s) ago
A meta-analysis suggests that abiraterone-based triplet therapy may be best for high-volume mCSPC, and API-based doublet regimens may be best for low-volume mCSPC.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Results shed light on which patients with metastatic castration-sensitive #prostateCancer are mostly likely to benefit from triplet therapy and which #mCSPC patients will likely benefit from doublet therapy. Published in @JAMAOnc. https://t.co/q6zGKjX6n2 #PCSM
-
-
Mashup Score: 0
At the 2022 Large Urology Group Practice Association (LUGPA) annual meeting, Alicia Morgans presented on couplet versus triplet therapy for metastatic castrate-sensitive prostate cancer (mCSPC). Biography: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Related Content: APCCC 2022:…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
#mCSPC Couplet vs Triplet Therapy. #LUGPA22 presentation by @CaPsurvivorship @DanaFarber. #WatchNow on UroToday > https://t.co/JZvzZ3SxOZ @UrologyUS https://t.co/VihYg5o6qJ
-
-
Mashup Score: 2
ASCO GU 2023 results from the PEACE-1 trial, de novo metastatic-castration sensitive prostate cancer (mCSPC), abiraterone acetate + prednisone to ADT +/- docetaxel in mCSPC, LATITUDE and STAMPEDE trials.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Efficacy and safety of abiraterone acetate + prednisone and ADT +/- docetaxel in older pts (≥70 Years), with de novo #mCSPC, compared to younger pts (70 Years): the #PEACE1 trial. Presented by Loic Mourey, MD. @ASCO #GU23 coverage by @zklaassen_md > https://t.co/ClzMhzYCdj https://t.co/pBTS68UsjB
-
-
Mashup Score: 08-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam - 1 year(s) ago
Gwenaëlle Gravis joins Alicia Morgans in a discussion on the PEACE-1 phase 3 trial 8-month PSA outcomes of men with metastatic castration-sensitive prostate cancer (mCSPC). In the PEACE-1 study, investigators evaluated the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care in de novo mCSPC. The 8-month PSA decline to undetectable…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
8-month PSA outcomes of men with #mCSPC in the #PEACE1 phase 3 trial. Gwenaëlle Gravis Mescam, MD @univamu joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/bFSrgjPKwk https://t.co/AD6kwzVHAu
-
-
Mashup Score: 1
At the 2022 Large Urology Group Practice Association (LUGPA) annual meeting, Alicia Morgans presented on couplet versus triplet therapy for metastatic castrate-sensitive prostate cancer (mCSPC). Biography: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Related Content: APCCC 2022:…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
#mCSPC Couplet vs Triplet Therapy. #LUGPA22 presentation by @CaPsurvivorship @DanaFarber. #WatchNow on UroToday > https://t.co/JZvzZ3SxOZ @UrologyUS https://t.co/PlGkRn5gbx
-
-
Mashup Score: 08-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam - 1 year(s) ago
Gwenaëlle Gravis joins Alicia Morgans in a discussion on the PEACE-1 phase 3 trial 8-month PSA outcomes of men with metastatic castration-sensitive prostate cancer (mCSPC). In the PEACE-1 study, investigators evaluated the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care in de novo mCSPC. The 8-month PSA decline to undetectable…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
8-month PSA outcomes of men with #mCSPC in the #PEACE1 phase 3 trial. Gwenaëlle Gravis Mescam, MD @univamu joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/bFSrgjPKwk https://t.co/UGbaHkXy6e
-
-
Mashup Score: 0Case Presentation: An 83-Year-Old Man with Biochemically Recurrent Metastatic Castration-Sensitive Prostate Cancer (mCSPC) - 1 year(s) ago
Sheela Tejwani, MD, presents the case of an 83-year-old man with mCSPC, and shares her first impressions as compared to her typical patients.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Sheela Tejwani, MD, presents the case of an 83-year-old man with #mCSPC, and shares her first impressions as compared with her typical patients. #pcsm | @HenryFordHealth https://t.co/GqP8WyBH10
-
-
Mashup Score: 0
Combining androgen deprivation therapy, docetaxel, and abiraterone in de novo metastatic castration-sensitive prostate cancer improved overall survival and radiographic progression-free survival with a modest increase in toxicity, mostly hypertension. This triplet therapy could become a standard of care for these patients.
Source: The LancetCategories: Hem/Oncs, Latest HeadlinesTweet-
3/ Another @US_FDA approved triplet therapy in de novo #mCSPC: abiraterone (+ ADT + docetaxel) improves OS and radiographic PFS compared to SOC±RT in the #PEACE-1 trial with modest⬆️toxicity (mainly HTN). #Fizazi @AlbertoBossial @GustaveRoussy @TheLancet https://t.co/1FaUwjpwLI https://t.co/ELMnwxcTKl
-
Listen to this discussion with Sheela Tejwani, MD, where she presents the case of an 83-year-old man with #mCSPC, and shares her first impressions as compared to her typical patients. #pcsm | @HenryFordHealth https://t.co/c4LglnAdpN